Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-244-4990
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.62 million
Profitability
Miscellaneous
Employees23
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions
What is Titan Pharmaceuticals' stock symbol?
Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."
When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?
Titan Pharmaceuticals shares reverse split on Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.
How were Titan Pharmaceuticals' earnings last quarter?
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its quarterly earnings data on Wednesday, August, 14th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.21. The specialty pharmaceutical company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.30 million. Titan Pharmaceuticals had a negative net margin of 352.17% and a negative return on equity of 412.65%. View Titan Pharmaceuticals' Earnings History.
When is Titan Pharmaceuticals' next earnings date?
What price target have analysts set for TTNP?
1 equities research analysts have issued 12 month price objectives for Titan Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Titan Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 809.1% from the stock's current price. View Analyst Price Targets for Titan Pharmaceuticals.
What is the consensus analysts' recommendation for Titan Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Titan Pharmaceuticals.
Has Titan Pharmaceuticals been receiving favorable news coverage?
Media stories about TTNP stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Titan Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Titan Pharmaceuticals.
Are investors shorting Titan Pharmaceuticals?
Titan Pharmaceuticals saw a decrease in short interest in July. As of July 31st, there was short interest totalling 808,200 shares, a decrease of 26.4% from the June 30th total of 1,098,200 shares. Based on an average daily volume of 269,300 shares, the days-to-cover ratio is presently 3.0 days. Currently, 6.5% of the company's shares are sold short. View Titan Pharmaceuticals' Current Options Chain.
Who are some of Titan Pharmaceuticals' key competitors?
Some companies that are related to Titan Pharmaceuticals include Microbot Medical (MBOT), Vical (VICL), Mateon Therapeutics (MATN), TrovaGene (TROV), TRACON Pharmaceuticals (TCON), Aevi Genomic Medicine (GNMX), aTyr Pharma (LIFE), Enzon Pharmaceuticals (ENZN), Vaxart (VXRT), CytRx (CYTR), CytRx (CYTR), Genetic Technologies (GENE), Proteon Therapeutics (PRTO), Vitro Diagnostics (VODG) and Neuralstem (CUR).
What other stocks do shareholders of Titan Pharmaceuticals own?
Who are Titan Pharmaceuticals' key executives?
Titan Pharmaceuticals' management team includes the folowing people:
- Dr. Marc Rubin, Exec. Chairman (Age 64)
- Mr. Sunil Bhonsle, Pres, CEO, Principal Financial Officer & Director (Age 69)
- Dr. Katherine L. Beebe-DeVarney Ph.D., Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer (Age 50)
Who are Titan Pharmaceuticals' major shareholders?
Titan Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.08%) and A.R.T. Advisors LLC (0.49%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Marc Rubin and Sunil Bhonsle. View Institutional Ownership Trends for Titan Pharmaceuticals.
Which institutional investors are buying Titan Pharmaceuticals stock?
TTNP stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and A.R.T. Advisors LLC. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Marc Rubin and Sunil Bhonsle. View Insider Buying and Selling for Titan Pharmaceuticals.
How do I buy shares of Titan Pharmaceuticals?
Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Titan Pharmaceuticals' stock price today?
One share of TTNP stock can currently be purchased for approximately $0.44.
How big of a company is Titan Pharmaceuticals?
Titan Pharmaceuticals has a market capitalization of $6.93 million and generates $6.62 million in revenue each year. The specialty pharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Titan Pharmaceuticals employs 23 workers across the globe.View Additional Information About Titan Pharmaceuticals.
What is Titan Pharmaceuticals' official website?
How can I contact Titan Pharmaceuticals?
Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SOUTH SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]
MarketBeat Community Rating for Titan Pharmaceuticals (NASDAQ TTNP)
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
